OPK

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2004, for eXegenics Inc. (Note: The request metadata listed "OPKO HEALTH, INC.", but the filing text identifies the registrant as eXegenics Inc.). The company, formerly a drug discovery firm, has terminated all research programs and is currently in a wind-down phase, identifying new business opportunities. As of November 9, 2004, the company had 16,227,914 shares of common stock outstanding.

Key Financial Metrics

Note: All figures are in thousands unless otherwise noted. The company reported no revenue for the current periods. Operating expenses were primarily General and Administrative costs totaling $399,000 for the quarter and $1,728,000 for the nine-month period.

Material Changes vs. Prior Period

• Revenue: The company reported zero revenue for the three and nine months ended September 30, 2004, compared to $13,000 in licensing fees for the same period in 2003.
• Operating Expenses: General and Administrative (G&A) expenses decreased significantly by 72% ($1,042,000) for the quarter and 54% ($2,031,000) for the nine months compared to 2003. This reduction is attributed to the completion of the wind-down of drug discovery operations and cost containment in legal and M&A expenditures.
• Strategic Redirection: Expenses related to strategic redirection were $0 in 2004, compared to $114,000 (quarter) and $561,000 (nine months) in 2003. All liabilities related to these redirections were recorded by December 31, 2003.
• Net Loss: Net loss attributable to common shareholders decreased to $(368,000) for the quarter and $(1,861,000) for the nine months, compared to $(1,525,000) and $(4,338,000) respectively in the prior year periods.

Outlook, Risks, and Management Commentary

• Business Status: The wind-down of operations was completed in the first half of 2004. The company is currently identifying new potential business opportunities but has not yet implemented a new strategy.
• Liquidity Forecast: Management forecasts cash usage of approximately $100,000 to $125,000 per month, assuming no new investments or business operations. Future capital needs are uncertain, and there is no guarantee that additional financing will be available on favorable terms.
• Delisting Risk: The company was notified by NASDAQ on July 26, 2004, of non-compliance with the minimum $1.00 closing bid price requirement. Despite a stay pending a hearing, the company's securities were delisted from the Nasdaq Small Cap Stock Market effective October 14, 2004.
• Legal Proceedings: The company is involved in the "Weiss Litigation" (a class action against former directors) and a federal lawsuit by a former employee ("Labidi Proceeding"). Management intends to defend these claims vigorously.
• Stock Split: A proposal for a one-for-two reverse stock split was defeated in July 2004 due to a lack of quorum at shareholder meetings.

Key Facts for Investor Verification

• Delisting Status: Verify the current trading venue of the stock following its delisting from NASDAQ on October 14, 2004.
• Cash Runway: Confirm the current cash balance against the stated burn rate of $100,000-$125,000 per month to assess immediate liquidity risk.
• Strategic Pivot: Investigate any announcements regarding the "new potential business opportunities" mentioned, as the company currently has no revenue-generating operations.
• Legal Exposure: Monitor the status of the Weiss Litigation and Labidi Proceeding for potential financial impact or settlement requirements.
• Preferred Stock: Note the existence of 965,249 shares of Series A convertible preferred stock with a liquidation value of $2,413,000, which ranks senior to common stock.